Postop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer

Prostate cancer is the second most common cancer among Canadian men of which approximately 20-30% present with high-risk tumour characteristic. Although surgery can be curative in patients evidencing pathological high-risk disease (extracapsular extension, seminal vesicle involvement, positive surgical margins), a large proportion will develop biochemical failure within years from the surgical procedure. The failure rate is even more pronounced in those patients that present with high prostate specific antigen (PSA) levels, pT3 disease, positive margins and Gleason score ≥8 with an estimated

Trial Details

NCT ID
NCT04249154
Phase
PHASE2
Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Eligard
Locations (sample)
  • Montreal, Quebec, Canada|45.50884,-73.58781
  • Montreal, Quebec, Canada|45.50884,-73.58781

Key Eligibility Criteria

  • Histologically proven high risk (any of the following risk factors: surgical positive margins; extra-capsular extension; seminal vesicle involvemen…
  • Histologically proven adenocarcinoma after a radical prostatectomy with pathologically negative lymph nodes (lymphadenectomy is not mandatory) or c…
  • Negative bone metastases proven by bone scan. The use of proton emission tomography (PET) fluoride is allowed
  • History and physical examination (including digital rectal exam) within 90 days prior of registration

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →